NASDAQ:MACK

Merrimack Pharmaceuticals Stock Forecast, Price & News

$7.80

-0.33 (-4.06 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.50

Now: $7.80▼

$8.13

50-Day Range

$3.83

MA: $6.86▼

$8.31

52-Week Range

$1.49

Now: $7.80▼

$8.86

Volume65,533 shs

Average Volume127,960 shs

Market Capitalization$104.36 million

P/E RatioN/A

Dividend YieldN/A

Beta2.55

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is based in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.08 out of 5 stars

Medical Sector

816th out of 1,558 stocks

Pharmaceutical Preparations Industry

390th out of 638 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Merrimack Pharmaceuticals.

2.9 Community Rank

Outperform Votes
Merrimack Pharmaceuticals has received 400 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merrimack Pharmaceuticals has received 297 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merrimack Pharmaceuticals has received 57.39% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote “Outperform” if you believe MACK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Merrimack Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Merrimack Pharmaceuticals does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merrimack Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $252,168.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 21.60% of the stock of Merrimack Pharmaceuticals is held by insiders.
Percentage Held by Institutions
52.25% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
Merrimack Pharmaceuticals has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:MACK

Previous Symbol

CUSIP59032810

CIK1274792

Webwww.merrimackpharma.com

Phone617-441-1000

Employees27

Debt

Debt-to-Equity RatioN/A

Current Ratio8.42

Quick Ratio8.42

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.30 per share

Price / Book6.00

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-17,330,000.00

Net MarginsN/A

Return on Equity-14.94%

Return on Assets-12.96%

Miscellaneous

Outstanding Shares13,380,000

Market Cap$104.36 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$7.80

-0.33 (-4.06 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

How has Merrimack Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MACK shares have increased by 182.6% and is now trading at $7.80.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Merrimack Pharmaceuticals?

Wall Street analysts have given Merrimack Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merrimack Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Merrimack Pharmaceuticals.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) issued its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter.
View Merrimack Pharmaceuticals' earnings history.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals's stock reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totaling 911,400 shares, an increase of 39.1% from the December 15th total of 655,100 shares. Based on an average daily volume of 1,400,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 6.9% of the company's stock are short sold.
View Merrimack Pharmaceuticals' Short Interest.

Who are some of Merrimack Pharmaceuticals' key competitors?

Some companies that are related to Merrimack Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of MACK's competitors.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the following people:

Mr. Gary L. Crocker M.B.A., MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman (Age 69, Pay $76k)
Dr. Ulrik B. Nielsen, Co-Founder & Independent Director (Age 49, Pay $67.62k)
Dr. Anthony J. Sinskey Ph.D., Sc.D., Co-Founder and Scientific Advisor (Age 81)
Geoffrey Grande C.F.A., Sr. Director of Communications
Ms. Ellen K. Forest, Head of HR (Age 57)
Dr. Fazal R. Khan Ph.D., Sr. VP of Manufacturing (Age 71)
Dr. Daryl C. Drummond Ph.D., Head of Research (Age 52)
Mr. Timothy R. Surgenor, Sec. (Age 61)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $7.80.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $104.36 million. Merrimack Pharmaceuticals employs 27 workers across the globe.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here